Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 20/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL748940 | 0.94 | CYP3A4 (0.65) | CYP3A4 | |
| SCHEMBL13763689 | 0.94 | CYP3A4 (0.70) | CYP3A4 | |
| SCHEMBL748213 | 0.94 | CYP3A4 (0.70) | CYP3A4 | |
| SCHEMBL2877953 | 0.94 | CYP3A4 (0.65) | CYP3A4 | |
| SCHEMBL10291426 | 0.94 | CYP3A4 (0.64) | CYP3A4 | |
| SCHEMBL2891845 | 0.94 | CYP3A4 (0.64) | CYP3A4 | |
| SCHEMBL748948 | 0.94 | CYP3A4 (0.64) | CYP3A4 | |
| SCHEMBL2891294 | 0.94 | CYP3A4 (0.64) | CYP3A4 | |
| SCHEMBL748838 | 0.93 | CYP3A4 (0.73) | CYP3A4 | |
| SCHEMBL747345 | 0.92 | CYP3A4 (0.65) | CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8138337-B2 | Reverse-turn mimetics and method relating thereto | CHOONGWAE PHARMA CORPORATION (KR) | 2012-03-20 | — | — | US | disclosed |
| US-8138337-B2 | Reverse-turn mimetics and method relating thereto | CHOONGWAE PHARMA CORPORATION (KR) | 2012-03-20 | — | — | US | disclosed |
| US-8080657-B2 | Compounds of reverse turn mimetics and the use thereof | CHOONGWAE PHARMA CORPORATION (KR) | 2011-12-20 | — | — | US | disclosed |
| US-8080657-B2 | Compounds of reverse turn mimetics and the use thereof | CHOONGWAE PHARMA CORPORATION (KR) | 2011-12-20 | — | — | US | disclosed |
| US-8049008-B2 | Reverse-turn mimetics and method relating thereto | CHOONGWAE PHARMA CORPORATION (KR) | 2011-11-01 | — | — | US | disclosed |
| US-8049008-B2 | Reverse-turn mimetics and method relating thereto | CHOONGWAE PHARMA CORPORATION (KR) | 2011-11-01 | — | — | US | disclosed |
| US-20100286094-A1 | NOVEL COMPOUNDS OF REVERSE TURN MIMETICS AND THE USE THEREOF | CHOONGWAE PHARMA CORPORATION (KR) | 2010-11-11 | — | — | US | disclosed |
| US-20100286094-A1 | NOVEL COMPOUNDS OF REVERSE TURN MIMETICS AND THE USE THEREOF | CHOONGWAE PHARMA CORPORATION (KR) | 2010-11-11 | — | — | US | disclosed |
| WO-2009051397-A9 | NOVEL COMPOUNDS OF REVERSE TURN MIMETICS AND THE USE THEREOF (3) | CHOONGWAE PHARMA CORPORATION (KR) | 2010-05-27 | — | — | WO | disclosed |
| US-7671054-B1 | Reverse-turn mimetics and method relating thereto | CHOONGWAE PHARMA CORPORATION (KR) | 2010-03-02 | — | — | US | disclosed |
| US-7671054-B1 | Reverse-turn mimetics and method relating thereto | CHOONGWAE PHARMA CORPORATION (KR) | 2010-03-02 | — | — | US | disclosed |
| WO-2009051397-A2 | NOVEL COMPOUNDS OF REVERSE TURN MIMETICS AND THE USE THEREOF (3) | CHOONGWAE PHARMA CORPORATION (KR) | 2009-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286094-A1 | NOVEL COMPOUNDS OF REVERSE TURN MIMETICS AND THE USE THEREOF | MCL1, MYADM, FLT3 | CYP3A4 3226/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.